Offices of Optometrists (U.S.) — NAICS 62132

An investor's primer. NAICS = North American Industry Classification System, the federal code system that defines an industry for official statistics. This page covers the five-digit NAICS industry 62132, one level up from the detailed national industry.

1. Overview

NAICS 62132 is the business of the neighborhood eye doctor: establishments run by an optometrist — a licensed O.D. (Doctor of Optometry) — who examines eyes, prescribes and fits glasses and contact lenses, and increasingly treats and monitors eye disease. It is a large, deeply fragmented health-care service industry of roughly 22,500 offices, ~148,000 workers, and about $20 billion in annual receipts, with no single firm holding even a small sliver of the market.[1][2]

The investment appeal is that eye care is recurring, insurance-supported, and demographically tailwinded — an aging, screen-heavy, increasingly diabetic population needs more exams over time. The catch is that this is not a clean, listed "sector": there is no U.S.-listed pure-play optometry office. Public-market investors reach it indirectly through optical retailers and product suppliers; private investors reach it directly by owning or backing practices and the platforms rolling them up. For the full analysis, see the child primer, NAICS 621320.

2. What's inside — and why this level equals its one child

The five-digit NAICS industry 62132 contains exactly one six-digit national industry:

• 621320 — Offices of Optometrists.

Because the parent has a single child, the two codes cover the identical set of establishments, revenue, and workers — 62132 is a pass-through, and its ground-truth statistics are the same numbers you see on the 621320 page. (NAICS uses one-to-one nesting like this wherever the U.S. did not split a five-digit industry into finer national detail.) The industry deliberately excludes several adjacent, larger money pools: ophthalmologists — physicians (M.D.s / D.O.s) who do eye surgery — are in NAICS 621111, Offices of Physicians; standalone eyewear stores are NAICS 456130, Optical Goods Retailers; and eyeglass/contact-lens manufacturing is NAICS 339115, Ophthalmic Goods Manufacturing.[4]

For everything below the headline — ownership models, practice economics, the investable names, regulation, and the consolidation thesis — read 621320 directly. This page gives only the rollup figures and the investor's short version.

3. Size (this level's rollup figures)

Federal statistics for NAICS 62132 (our ground-truth figures):

More establishments (22,501) than firms (18,582) tells you many owners run more than one office, but only modestly — this is a small-shop industry. Dividing receipts by firms implies roughly $1.1 million of revenue per firm (about $0.9 million per establishment).

Undercount caveat — the official figure understates the full optometry economy, and cuts one way:

• Employees are not optometrists. The 147,931 paid employees include front-desk staff, opticians, and technicians alongside employed O.D.s. Separately, the BLS (Bureau of Labor Statistics) counts about 47,800 optometrist jobs across all settings in 2024 — many working outside these offices, inside optical retailers (456130) or physician/hospital groups (621111).[5] So this code captures only the standalone-office slice of U.S. optometry.
• The whole eye-care wallet is bigger. So much optometry happens inside retail chains and private-equity platforms whose revenue books legally as retail that private vendors put the broader optometrist market nearer $23 billion — still highly fragmented, with no company much above ~5% share.[5] Treat the $20.1 billion Census figure as the conservative, definition-strict number.

The federal extract contains no industry-level margin, EBITDA, exam-volume, or payer-mix figure, and mixes vintages (receipts 2022; payroll and employment 2023), so it cannot be used to back out an industry margin. Practice-level economics in the child primer come from trade sources, flagged as such.

4. Investable universe (where value concentrates)

Because 62132 has a single child, value concentrates exactly where it does in 621320: around the exam chair, not in it. There is no U.S.-listed pure-play optometry office. Public exposure comes through:

• Optical retailers that host or employ O.D.s — National Vision (ticker EYE) and Warby Parker (WRBY); you are mostly buying retail unit economics and eyewear margins, with optometry as the traffic driver.
• The vertically integrated eyewear giant — EssilorLuxottica (EL / ESLOY), which makes the lenses and frames, owns LensCrafters and Pearle Vision, and owns the EyeMed vision-insurance plan.
• Upstream product suppliers — CooperCompanies (COO, contact lenses) and Alcon (ALC).

The independent-practice side is a private owner-operator world now being rolled up by management-services organizations (MSOs) and private-equity (PE) platforms — e.g., MyEyeDr. and EyeCare Partners — and shaped by large vision-benefit payers such as VSP Vision. Full company detail, tickers, and platform profiles are in 621320, Section 4.

5. How the money works

An optometry office is a hybrid: part health-care service, part specialty retailer. Revenue splits into professional fees (the exam and medical eye care, roughly 55% of revenue) and dispensing/optical (glasses and contacts, over 40%, where much of the margin lives — eyewear carries ~50–70% gross margins).[6] The levers an operator manages are capture rate (share of exam patients who buy eyewear on-site), revenue per exam (lifted by premium lenses and by billing medical eye care rather than thin routine-vision plans), chair time / doctor utilization, and payer mix. These are trade-source benchmarks, not federal data — the official file carries none. See 621320, Section 5 for the full breakdown.

6. Demand drivers

Demand is non-cyclical and slowly growing, driven more by biology and demographics than by the economy: aging (presbyopia, cataracts, glaucoma, macular degeneration), chronic disease (diabetes and hypertension, which push optometry into higher-reimbursing medical care), refractive error (rising myopia with screen time), insurance and employer vision benefits, and medical scope expansion where state law permits. BLS projects optometrist employment to grow 8% from 2024 to 2034, faster than average.[5] The principal near-term constraint is clinician supply — an office with demand but no O.D. coverage cannot monetize its exam rooms.

7. Regulation

Optometry is one of the most regulation-shaped small industries because it blends health care, retail, insurance, and prescription products. The key regimes: state licensure and scope of practice (a continuous state-by-state fight with ophthalmology); FTC (Federal Trade Commission) prescription-release rules — the Eyeglass Rule and the Contact Lens Rule — that deliberately let patients take their prescription elsewhere and buy eyewear online, a structural headwind to capture rate; FDA (Food and Drug Administration) regulation of contact lenses as medical devices; Medicare, which generally excludes routine exams and eyewear but covers certain disease-related services; and corporate-practice-of-medicine (CPOM) rules that shape how PE structures ownership through an MSO plus a doctor-owned professional entity. Full detail in 621320, Section 7.

8. Consolidation

Federal concentration data confirm an unusually fragmented industry: the four largest firms hold just 7.8% of receipts (CR4), the top fifty only 16.4% (CR50), and the Census Herfindahl-Hirschman Index (HHI) — a 0–10,000 concentration gauge where regulators treat anything below 1,500 as "unconcentrated" — is a rock-bottom 21.7.[2] That fragmentation is the entire thesis for consolidators. The structure is now a three-way contest among national optical retailers, MSO/PE roll-ups, and surviving independents. Independent practices have traded around 3–6x EBITDA (earnings before interest, taxes, depreciation, and amortization), with platforms in the low-to-mid teens; multiples compressed as financing got more expensive.[7] See 621320, Section 8.

9. Risks

The same risks that define 621320 apply in full: disintermediation of eyewear (online sellers plus FTC prescription-release rules chipping at the optical margin that funds the practice); reimbursement/vision-plan squeeze (thin, rarely-rising eyewear payments); clinician scarcity (only ~8% job growth 2024–2034, leaving fixed rent and staff underused when doctors are absent);[5] PE over-leverage and integration risk; regulatory fragmentation and reversals on state scope and CPOM; clinical/legal liability; and discretionary/cyclical eyewear, since frames and premium lenses are deferrable in a downturn.

10. How to invest & outlook

Because 62132 is a single-child pass-through, the playbook is identical to 621320. Public routes: the cleanest listed operating exposure is value retail (National Vision, EYE); Warby Parker (WRBY) is the growth/brand bet; EssilorLuxottica (EL / ESLOY) owns the whole eyewear-and-insurance stack; CooperCompanies (COO) and Alcon (ALC) are upstream product plays. Private routes — where most of the actual "offices of optometrists" economics live — are buying or backing independent practices, investing in or lending to MSO/PE platforms, or owning the small-format medical-retail real estate these offices lease; underwrite the practice, the doctor relationship, and the legal structure separately.

Outlook. The demand backdrop is dependable and slowly rising — aging eyes, worsening myopia, and more medical eye disease should keep exam volumes growing through the next decade, and optometry's push into medical care is the most attractive margin lever. The structural tension is between that steady clinical demand and a persistently squeezed retail margin. For public investors the bet is largely on retail execution; for private investors it is on buying durable local practices at sensible multiples, with a clean legal structure, before the roll-ups do. For the complete analysis, read the child primer, NAICS 621320.

---

Sources

1. U.S. Census Bureau. "County Business Patterns, 2023 — NAICS 621320 Offices of Optometrists" (establishments, employment, annual and Q1 payroll). https://www.census.gov/programs-surveys/cbp.html
2. U.S. Census Bureau. "2022 Economic Census — Concentration of Largest Firms, NAICS 621320" (receipts, firm count, CR4/CR8/CR20/CR50, HHI). https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
3. U.S. Census Bureau. "NAICS 2022 — 621320 Offices of Optometrists (definition and exclusions)." https://www.census.gov/naics/?input=621320&year=2022
4. U.S. Bureau of Labor Statistics. "Occupational Outlook Handbook: Optometrists" (2024 employment ~47,800, median wage, 8% projected growth 2024–2034). https://www.bls.gov/ooh/healthcare/optometrists.htm
5. IBISWorld. "Optometrists in the US — Industry Report" (broader market size ~$23B, fragmentation). https://www.ibisworld.com/united-states/industry/optometrists/1560/
6. Review of Optometric Business / BCAT. "Optometry Practice Finances: Revenue & Profit Benchmarks" (revenue split, capture rate, eyewear/contact margins). https://mybcat.com/blog/optometry-practice-finances/
7. Physician Growth Partners. "State of Eye Care Private Equity and Optometry M&A Multiples," 2025. https://physiciangrowthpartners.com/white-paper/state-of-eye-care-private-equity-q1-2025/